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Introduction: The aim of this study was to evaluate the safety and efficacy of rituximab (RTX) in a large cohort of
patients with rheumatoid arthritis in routine care, and to monitor changes in daily practice since the introduction
of RTX therapy.
Methods: This was a multicentre, prospective, non-interventional study conducted under routine practice conditions
in Germany. Efficacy was evaluated using Disease Activity Score in 28 joints (DAS28) and Health Assessment
Questionnaire-Disability Index (HAQ-DI). Safety was assessed by recording adverse drug reactions (ADRs). Physician and
patient global efficacy and tolerability assessments were also evaluated.
Results: Overall, 2,484 patients (76.7% female, mean age 56.4 years, mean disease duration 11.7 years) received RTX
treatment (22.7% monotherapy). The total observation period was approximately six-years (median follow-up
14.7 months). RTX treatment led to improvements in DAS28 and HAQ-DI that were sustained over multiple courses.
DAS28 improvements positively correlated with higher rheumatoid factor levels up to 50 IU/ml. Response and tolerability
were rated good/very good by the majority of physicians and patients. Mean treatment intervals were 10.5 and 6.8 months
for the first and last 400 enrolled patients, respectively. Infections were the most frequently reported ADRs (9.1%; 11.39/
100 patient-years); approximately 1% of patients per course discontinued therapy due to ADRs.
Conclusions: Prolonged RTX treatment in routine care is associated with good efficacy and tolerability, as measured by
conventional parameters and by physicians’ and patients’ global assessments. Rheumatoid factor status served as a
distinct and quantitative biomarker of RTX responsiveness. With growing experience, physicians repeated treatments
earlier in patients with less severe disease activity.Introduction
The anti-CD20 monoclonal antibody rituximab (RTX) was
licensed in 2006 in combination with methotrexate (MTX)
for the treatment of severe, active rheumatoid arthritis
(RA) in adult patients with an inadequate response to
disease-modifying antirheumatic drugs (DMARDs) includ-
ing one or more tumour necrosis factor (TNF) inhibitors.
Based on the pioneering idea that RTX might be of value in* Correspondence: joerg.wendler@pgrn.de
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reproduction in any medium, provided the orthe treatment of seropositive RA, a proof of concept study
confirmed its efficacy and safety in combination with MTX
and thereby provided strong evidence for the role of B cells
in this disease [1]. RTX is distinct from other biological
DMARDs, with regards to its mode of action which in-
volves the targeting of CD20+ B cells resulting in the inhib-
ition of B-cell-mediated inflammatory responses. Another
unique feature of RTX is the long interval between treat-
ment courses; the selective depletion of CD20-positive B
cells by RTX results in a long duration of therapeutic re-
sponse with each course of treatment [2]. RTX retreatment
is generally recommended at around six months based onl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ministered using monthly or more frequent regimens. The
less frequent dosing schedule of RTX means that more pro-
longed follow-up may be needed in order to properly evalu-
ate physicians’ and patients’ experiences with this therapy.
Extensive data on the long-term efficacy and safety
profile of RTX are now available, mainly from long-term
follow-up of patients participating in the RTX clinical
trial programme. Five-year efficacy data from the RE-
FLEX trial extension have recently been reported [4], as
have been safety data from a pooled analysis of all RTX
clinical trials with a follow-up of 10 years, involving up
to 17 courses [5]. However, clinical trials are biased by
the requirements of patient exclusion and inclusion cri-
teria, and it is estimated that only about 30% of daily
practice patients would be eligible for such studies [6].
Consequently, data obtained in real-life settings are also
valuable. Such data from RTX-treated patients have been
reported from a number of European registries, although
generally involving relatively shorter periods of follow-
up [7-11].
This very large, non-interventional study was initiated in
Germany in 2006 when RTX was first authorised for RA
treatment. The main purpose of the study was to evaluate
the safety and efficacy of RTX in routine RA care. An add-
itional objective was to monitor changes in daily practice
during the period following the introduction of RTX, for
example, with regard to retreatment or concomitant ther-
apy, and whether specific variables, such as patient age, in-
fluence treatment outcomes.
Materials and methods
Study design
This was a multicentre, prospective, non-interventional
study, the primary objective of which was to assess the
long-term efficacy and safety of RTX in patients with ac-
tive RA in a routine practice setting. Participating physi-
cians were rheumatologists practising at 215 outpatient
clinics or private practices in Germany. A list of study in-
vestigators and sites is provided in Additional file 1. Pa-
tients received RTX treatment and retreatment according
to the discretion of the physician. Patient data were col-
lected for a period of two years after the start of the first
RTX treatment course. If patients required retreatment,
the two-year observation period was restarted at the point
of RTX retreatment. Clinical visits were documented at
baseline (first infusion), Day 15 (second infusion) and, as
available, at months 4, 8, 12, 16, 20 and 24.
In accordance with Section 67, Sub-Section 6 of the
German Drug Law, the Federal Panel Doctors' Associ-
ation, the Central Federal Association of health insurance
funds and the competent higher federal authority were no-
tified regarding the conduct of this non-interventional
study. Ethical approval of the study and patient writtenconsent were not obtained as neither was mandatory in
Germany for non-interventional studies when the study
commenced in 2006. The study was conducted in accord-
ance with the principles of the Declaration of Helsinki.
Assessments
The main parameter for evaluating efficacy was the Disease
Activity Score in 28 joints (DAS28). Assessment of func-
tional disability was performed using the Health Assess-
ment Questionnaire-Disability Index (HAQ-DI). Safety was
assessed by the occurrence of adverse drug reactions
(ADRs) and infusion reactions (IRs). Measurement of
rheumatoid factor (RF) was performed at the individual
study sites, using nephelometry which primarily detects
IgM RF. All clinical assessments were made by fully trained
qualified health care professionals, although we accept that
some degree of variation in both the competence and tech-
niques applied across >200 outpatient clinics and private
practices is likely to have occurred and may have influenced
the results to some extent. Additionally, physicians and pa-
tients were asked to assess the global efficacy and tolerabil-
ity of RTX therapy using the following four categories: very
good, good, moderate and poor.
Statistical analyses
The safety population comprised all patients who had re-
ceived at least one RTX infusion. The efficacy population
comprised all patients with a primary diagnosis of RA and
in whom at least one post-baseline efficacy measurement
had been documented. All efficacy and safety parameters
were analysed descriptively using SAS version 8.2 software
(SAS Institute, Cary, North Carolina, USA). For numerical
data, mean, standard deviation, median, range and inter-
quartile ranges were calculated. Categorical data were ana-
lysed by calculating absolute and relative frequencies.
Missing values were not imputed. Changes from baseline in
efficacy parameters were used as outcome variables. Sub-
group analyses were performed based on the following pa-
rameters: time of inclusion (first 400 enrolled patients
versus last 400 enrolled patients), RF level, age and sex.
Due to decreasing patient numbers with each treatment
course, the efficacy evaluations in this analysis focused on
the first three treatment courses. Correlation between base-
line RF level and change in DAS28 was analysed using the
Locally Estimated Scatterplot Smoothing (LOESS) non-
parametric regression method [12]. In brief, this involves
the selection of a specific span (bandwidth) of points along
the x-axis adjacent to the point being predicted. A regres-
sion equation is then fitted for the selected points through
this subset of data giving more weight to points closest to
the value being predicted. The resulting equation is then
used to predict the value for the selected point. The data
are then shifted one point to the right and the process is re-
peated. The resulting predicted values and confidence limits
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bandwidth, the less smooth the final line. To improve the
comparability of the data, the LOESS analysis included the
subgroup of seropositive and seronegative patients with RF
levels determined using the most frequently used diagnostic
tests (normal ranges of <14, 15 or 20 IU/ml).
Results
Data from 2,484 patients including all treatment courses
over a period of approximately six years (median follow-
up 14.7 months, range 0.0 to 64.8 months) were col-
lected. The safety population comprised 2,484 patients,
while the efficacy population comprised 2,424 patients.
Consistent and evaluable efficacy data for at least three
RTX treatment courses were available for a subgroup of
902 patients (the evaluable efficacy population). Most
patients (98.1%) were treated using RTX 2 × 1,000 mgTable 1 Demographics and baseline characteristics
Safe
(
Female, n (%)
Age (years), mean ± SD 56.4 ±
Duration of disease before study, years, mean ± SD 11.7
RF-positive, n (%) 1477
Treatment duration (months) over all study courses, mean ± SD 17.2 ±
No. of previous DMARD baseline treatments including
TNF antagonists, median
No. of previous conventional DMARD baseline treatments, median
No. of baseline TNF antagonists, median†
Previous TNF antagonists, n (%)†
0
1
2
3
No. of different TNF antagonists per patient, mean ± SD
Most frequent previous
DMARD baseline treatments, n (%)
Leflunomide
Methotrexate
Adalimumab
Etanercept
Sulphasalazine
Infliximab
Baseline DAS28, mean ± SD‡ 5.7 ±
Baseline HAQ, mean ± SD‡ 1.6 ±
Time between first and second course (months), mean ± SD‡ 9.6 ±
*Missing values were not imputed. Total patient number was 2,484, unless stated. †
‡Efficacy population.
DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic
standard deviation; TNF, tumour necrosis factor-alpha.per course. Times to retreatment changed during the
course of the study, and with each additional course. In
the efficacy population, the mean retreatment interval was
9.6 months between courses 1 and 2, and 7.7 months be-
tween courses 5 and 6. Demographics and baseline char-
acteristics are summarised in Table 1.
Efficacy
In the efficacy subgroup, baseline DAS28 scores at courses
1, 2 and 3 were 5.7, 5.0 and 4.6, respectively. Mean change
from baseline in DAS28 during the first treatment course
was -1.4 points at month 4 and -1.4 points at month 8.
After three treatment courses, mean DAS28 decreased to
3.6 at both the four-month and eight-month time points.
In parallel with the improvements in DAS28 score, an in-
creasing proportion of patients achieved low disease activ-
ity (LDA) status with each additional treatment course.ty population
n = 2,484*)
Patients enrolled early
(n = 400)
Patients enrolled late
(n = 400)
1906 (76.7) 302 (75.5) 326 (81.5)
12.4 (n = 2,474) 55.1 ± 12.1 56.9 ± 12.4
± 9.6 (n = 2,168) 12.3 ± 9.3 11.9 ± 9.9
(77.3) (n = 1,910) 277 (78.5) (n = 353) 232 (77.6) (n = 299)
13.7 (n = 2,484) 22.4 ± 17.0 9.1 ± 7.9
4 5 4
3 3 2
1 2 1
510 (20.5) 66 (16.5) 89 (22.3)
827 (33.3) 93 (23.3) 163 (40.8)
785 (31.6) 135 (33.8) 122 (30.5)
362 (14.6) 106 (26.5) 26 (6.5)
1.4 ± 1.0 1.7 (1.0) 1.2 (0.9)
1690 (68.0) 285 (71.3) 256 (64.0)
1661 (66.9) 291 (72.8) 276 (69.0)
1385 (55.8) 245 (61.3) 200 (50.0)
1360 (54.8) 265 (66.3) 205 (51.3)
1145 (46.1) 215 (53.8) 168 (42.0)
736 (29.6) 171 (42.8) 80 (20.0)
1.2 (n = 1,954) 5.9 ± 1.2 (n = 384) 5.4 ± 1.3 (n = 349)
0.7 (n = 2,078) 1.74 ± 0.70 (n = 389) 1.56 ± 0.73 (n = 384)
4.4 (n = 1,306) 10.5 ± 4.9 (n = 250) 6.8 ± 1.6 (n = 143)
For course 1.
drug; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SD,
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at baseline prior to course 1 to 23.7% (course 1, month 8),
30.8% (course 2, month 8) and 42.4% (course 3, month 8).
Patients with exposure to more than one previous TNF in-
hibitor also benefitted from RTX retreatment: the propor-
tion of patients with DAS28 remission increased from
9.8% (course 1, month 8) to 29.5% (course 3, month 8).
Physician-reported mean swollen joint count (28 joints)
decreased from 7.9 at baseline to 4.1 at month 4, and to 4.1
at month 8 of course 1, with further decreases observed
during each subsequent course. In parallel, tender joint
count (28 joints) decreased from 11.0 at baseline to 6.1 at
month 8 of course 1, and to 4.3 at month 8 of course 3.
During the first treatment course, mean HAQ-DI values
showed clinically meaningful improvements (a decrease of
>0.22 points) of 0.22 points between baseline and month 4
and of 0.24 points between baseline and month 8. High
proportions of patients showed a clinically meaningful de-
crease of HAQ-DI at month 8 following each RTX course
even though the baseline values were lower: course 1,
48.6%; course 2, 42.0%; course 3, 32.6%.A)
B)
Figure 1 Efficacy of rituximab as monotherapy and in combination w
changes are with reference to the baseline values at each course. DAS28: D
Questionnaire-Disability Index, LEF: leflunomide, MTX: methotrexate, RTX: riSubgroup analyses
A total of 564 patients (22.7%) received RTX as mono-
therapy. This subgroup was comparable to the total
population with regard to demographic and baseline
characteristics (76.4% female; mean age 59.3 years; mean
disease duration 12.6 years; 79.2% RF-positive; and a me-
dian of four (mean 4.6) previous conventional DMARD
therapies and a median of one (mean 1.4) previous TNF
inhibitor). The efficacy of RTX monotherapy was com-
parable to that of RTX combined with MTX (n = 879)
and leflunomide (LEF) (n = 215), with similar results for
the investigated parameters, including DAS28, HAQ-DI
(Figure 1) and time intervals between treatments.
Efficacy outcomes were also analysed according to patient
age group (Table 2). Changes in DAS28 during courses 1
and 2 were similar in age groups <40 years, 40 to <60 years
and ≥60 years.
The first 400 patients entered the study between July
2006 and February 2007, while the last 400 patients were
enrolled between January and October 2009. The inter-
val between these two periods was shorter than initiallyith methotrexate and leflunomide. A) DAS28 and B) HAQ-DI. The
isease Activity Score in 28 joints, HAQ-DI: Health Assessment
tuximab.
Table 2 Overview of safety and efficacy of RTX treatment
stratified by age
All
patients
Age group (years)
<40 40 to <60 ≥60
Safety, n (%)
No. of patients 2,484 204 1,187 1,029
ADRs 532 (21.4) 52 (25.5) 264 (22.2) 200 (19.4)
Serious ADRs 76 (3.1) 5 (2.5) 30 (2.5) 33 (3.2)
Infusion reactions 157 (6.3) 25 (12.3)* 83 (7.0)* 42 (4.1)*
Deaths 9 (0.4) 0 3 (0.3) 6 (0.6)
Efficacy, DAS28
(mean [SD])
Course 1
No. of patients
(baseline)
1,954 163 975 814
Baseline 5.7 (1.2) 5.3 (1.3) 5.7 (1.2) 5.8 (1.2)
Month 4 4.3 (1.4) 4.0 (1.5) 4.3 (1.4) 4.3 (1.3)
Month 8 4.3 (1.4) 3.8 (1.7) 4.4 (1.5) 4.3 (1.3)
Course 2
No. of patients
(baseline)
1,315 117 660 537
Baseline 5.0 (1.3) 4.7 (1.5) 5.0 (1.3) 5.1 (1.2)
Month 4 4.0 (1.3) 3.6 (1.4) 4.0 (1.4) 4.0 (1.3)
Month 8 4.0 (1.4) 3.5 (1.6) 4.1 (1.3) 3.9 (1.4)
*Significantly different between age groups; P <0.005 (Fisher’s exact test).
ADR, adverse drug reaction; DAS28, Disease Activity Score in 28 joints; RTX,
rituximab; SD, standard deviation.
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physicians tended to include patients with less severe dis-
ease later in the study; baseline DAS28 was higher in the
early group compared with the later group (mean 5.9 ver-
sus 5.4). In addition, patients in the early group had re-
ceived a greater median number of DMARDs at baseline
(5.1 versus 3.8) and were on average slightly younger than
those in the later group (55.1 versus 56.9 years). The mean
time to retreatment was considerably longer in the early
group compared with the later group (10.5 versus
6.8 months) (Table 1).
In order to assess the influence of serological status on
responsiveness to RTX, the efficacy population was strati-
fied according to RF levels at baseline. Analysis across these
subgroups revealed that both DAS28 and HAQ-DI tended
to show greater reductions over four and eight months in
patients with higher RF levels at baseline (Figure 2). This
trend was observed for all treatment courses.
Based on the data obtained by LOESS analysis, a direct
correlation between baseline RF levels and responsiveness
to RTX was found (spearman correlation coefficient 0.21;
Figure 3). Responsiveness to RTX, in terms of DAS28
change from baseline at four months, improved in associ-
ation with increased RF level up to approximately 50 IU/ml. Baseline RF level above 50 IU/ml was not associated
with any further increase in RTX responsiveness. The
LOESS analysis confirmed that RF-positive patients re-
spond better to RTX.
Global assessment of efficacy and tolerability
The efficacy and tolerability of RTX treatment were rated
to be good or very good by the majority of patients and
physicians (Figure 4). At month 8 of course 1, 75.0% of
physicians and 71.5% of patients considered the efficacy of
RTX to be good or very good, while 98.6% of physicians
and 92.7% of patients rated the tolerability of RTX to be
good or very good. Ratings tended to improve during sub-
sequent courses. In spite of the high overall percentage of
good to very good ratings, corresponding to a generally
good acceptance, patients tended to give slightly lower rat-
ings than physicians.Safety
ADRs were reported in 532 patients (21.4%; 39.58/100
patient-years) overall (Table 2). The most frequent ADRs
were infections and parasitic diseases (9.1%; 11.39/100
patient-years), with the most frequent infection being
nasopharyngitis (1.8%; 1.61/100 patient-years). Skin and
subcutaneous tissue disorders were also common (5.5%;
5.48/100 patient-years), and mainly pruritus (1.5%; 1.39/
100 patient-years). All other reported ADRs occurred at
a frequency of <5% (<5/100 patient-years). Serious ADRs
were reported by 76 patients (3.1%; 4.44/100 patient-
years). Overall, IRs were reported in 157 patients (6.3%;
3.62/100 patient-years). The incidence of IRs was highest
during course 1 (4.3% (95/2,195)) and then declined with
subsequent courses (3.0% (46/1,509)) for course 2 and
1.8% [16/909] for course 3. RTX infusions were inter-
rupted due to ADRs in 30 patients. Nine patients (0.4%;
0.40/100 patient-years) had serious IRs.
Cases of sepsis were rare: general sepsis (n = 3), septic
shock (n = 2), and urosepsis (n = 1). Single cases of the fol-
lowing fungal infections were reported (as described in the
safety report): fungal infection, sinusitis due to fungal in-
festation, tinea corporis, tinea pedis, dermal fungal infec-
tion, gastointestinal candidosis, oral candidosis, vaginal
candidosis and vulvovaginal fungal infection. No cases of
hepatitis or atypical mycobacterial infection were reported.
One patient died who had tuberculosis and sepsis. No
cases of progressive multifocal leukoencephalopathy were
reported throughout the observation period.
The proportions of patients reporting ADRs and serious
ADRs were also similar in the three age groups. There
were no apparent differences between RF-positive and RF-
negative patients in the frequency of overall ADRs (23.1
versus 21.1%, respectively) or serious infections and para-
sitic diseases (1.2 versus 0.9%, respectively).
A)
B)
Figure 2 Changes from baseline in DAS28 and HAQ-DI according to baseline rheumatoid factor level. A) DAS28 and B) HAQ-DI. DAS28:
Disease Activity Score in 28 joints, HAQ-DI: Health Assessment Questionnaire-Disability Index.
Wendler et al. Arthritis Research & Therapy 2014, 16:R80 Page 6 of 9
http://arthritis-research.com/content/16/2/R80Nine patients died during the study. Six of these
deaths were considered not related to RTX. In one case
causality was assessed as not applicable and two cases
were assessed as possibly related (one patient died due
to postoperative complications including sepsis and the
other due to an acute respiratory distress syndrome).
Discussion
Non-interventional studies can provide valuable data
with regard to the efficacy and safety of therapies in a
real-life setting. This study, conducted in routine clinical
practice in Germany over a period of approximately six
years starting soon after the marketing authorisation of
RTX, is possibly the largest of its type with the inclusion
of over 2,400 patients. The results indicate that RTX
treatment was associated with favourable efficacy out-
comes over multiple courses, with significant decreases
in DAS28 accompanied by clinically meaningful changes
in HAQ-DI. The findings are in line with those previ-
ously reported from RTX clinical trials [4,13] and Euro-
pean registries [7,8,10]. In addition, the results provide
convincing documentation of changes in clinical practiceover time and the first evidence indicating a quantitative
relationship between RF level and response to RTX. A
sub-analysis of our study further demonstrated the ef-
fectiveness of RTX in older patients, with outcomes ob-
served in patients over 60 years of age comparable with
those seen in younger patients. Interestingly, IRs were
less frequent in patients of 60 years or older compared
with patients younger than 60 years old. To our know-
ledge this is the first report of the influence of age on
RTX efficacy and safety.
A longitudinal analysis of the data suggests that there
have been some changes in physicians’ practices since
RTX was first licensed for treatment of RA in 2006. By
comparing data from the first 400 enrolled patients with
those from the last 400 enrolled patients, a period sepa-
rated by approximately 2.5 years, the results suggest that,
over time, physicians changed to using RTX in patients
with less severe disease. In addition, RTX retreatment in-
tervals generally shortened over the time of the study.
These observations of changes in daily practice likely re-
flect the introduction into clinical practice in Germany of
guidelines recommending a treatment to target approach
Upper/lower
90% confidence
interval
Ch
an
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Figure 3 LOESS analysis of the relation between RF level and DAS28. Each data point indicates change in DAS28 from baseline at month 4.
DAS28: Disease Activity Score in 28 joints, RF: rheumatoid factor.
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that a small minority (approximately 3.5%) of patients
were treated with rituximab despite having LDA; the rea-
sons for this non-standard approach are not clear as this
information was not collected during the study. However,
a number of explanations are possible, including individ-
ual consideration of patient treatment according to disease
history; discontinuation of prior therapy due to intolerabil-
ity while having LDA; or physician preference to target re-
mission even when LDA had been achieved.
The summary of product characteristics recommends
that RTX is administered in combination with MTX [16].A)
C)
B
D
Figure 4 Global ratings of efficacy and tolerability by physicians and
physician. C) Efficacy, patient. D) Tolerability, patient.It is interesting to note, therefore, that nearly one-quarter
(23%) of patients in the current study received RTX as
monotherapy. The reasons for this relatively high propor-
tion are not clear. MTX may be contraindicated in some
patients and not tolerated by others, although other rea-
sons, such as physicians’ or patients’ preference, may also
have been involved. The efficacy outcomes associated with
RTX monotherapy were generally similar to those achieved
with RTX in combination with MTX or LEF. Interestingly,
the present analysis of the complete data set differs from a
previous interim analysis of 995 patients, which indicated
that RTX plus LEF provided superior outcomes (EULAR)
)
patients during course 1. A) Efficacy, physician. B) Tolerability,
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studies have reported that RTX monotherapy is similar to
RTX plus MTX in terms of short-term efficacy [18,19],
while another study reported that RTX plus LEF gave better
outcomes than RTX alone or in combination with MTX
[20]. Data from a phase II trial indicated that the probability
of achieving higher hurdle clinical endpoints, such as
ACR50 or ACR70, is increased when RTX is administered
in combination with MTX rather than as monotherapy [1].
Patients seropositive for RF have been shown previ-
ously to exhibit greater efficacy responses to RTX than
those who are seronegative [7,9,11,18,21,22]. In this
non-interventional study, patients with higher RF levels
tended to have greater DAS28 and HAQ responses than
those with lower levels. These data further support the
use of RF status as a biomarker for predicting RTX re-
sponsiveness and may extend this correlation to a quanti-
tative relationship. The results of the LOESS analysis
indicated that RTX responsiveness increases up to an RF
level of approximately 50 IU/ml, with no further increases
seen above this level. Although seronegative and low-level
RF positive patients tended to respond less well to RTX,
the results indicate that some of these patients, perhaps
around 50%, may still benefit from RTX therapy.
The safety profile of RTX has been established primarily
from long-term follow-up of patients in the RTX clinical
trial programme [5,23]. Real-life studies, such as the current
non-interventional study, are invaluable as they include pa-
tients with significant comorbidities or other demographic
and disease characteristics that would exclude them from
formal clinical trials. RTX was rated as good or very good
in terms of both efficacy and tolerability by the majority of
physicians and patients in this study. As would be expected
from a real-life study, the proportion of patients reporting
ADRs was generally lower than that reported in the RTX
clinical trials [5,23].
The study has a number of possible limitations due to
the non-interventional design with lack of a control group
that limit a more reliable evaluation of efficacy and toler-
ability of RTX. Moreover, adverse event rates may be
underestimated due to less stringent requirements when
compared with randomised clinical trials. Finally, assess-
ment of subgroups (for example, age) was somewhat lim-
ited by smaller patient numbers in these groups. Despite
these limitations, the study provides insights into daily clin-
ical practice beyond a rather selected patient group often
enrolled in clinical studies.
Conclusions
In conclusion, the results of this large non-interventional
study involving 2,484 patients with observation over six
years indicate that RTX is efficacious and well tolerated in
routine care in Germany, including in older patients, with
improved efficacy results in RF-positive patients. Inaddition, the results demonstrate that RTX monotherapy
and in combination with LEF may represent an alternative
for some patients intolerant to MTX. This study also pro-
vides evidence that changes in the use of RTX to treat RA
have occurred in recent years, thus indicating that physi-
cians have adopted this therapy and have developed how
it is used in routine care.
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